Список проголосовавших за комментарий " CymaBay Therapeutics upgraded to Buy at H.C. Wainwright; tgt raised to $6 (1.67)H.C. Wainwright upgrades CBAY to Buy from Neutral and raises their tgt to $6 from $2.50. Firm's positive outlook on the shares is driven by two major factors: 1) potential aggregate milestone payments totaling up to $200M from Kowa (Japan), CymaBay's new U.S. partner for arhalofenate (gout), which they initially did not incorporate into their model when the agreement was announced earlier this month, and 2) a more positive view of the potential of MBX-8025 to treat PBC in the ongoing open-label, dose ranging Phase 2 study."